Cargando…

New Therapeutic Targets in Rheumatoid Arthritis

The volume focuses on therapeutic targets that were identified after TNF blockade and that have recently been registered or are currently under development for the treatment of rheumatoid arthritis. Each chapter discusses the biological rationale in great detail, including in vitro work and work in...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor Corporativo: SpringerLink (Online service)
Otros Autores: Tak, Paul-Peter (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Basel : Birkhäuser Basel : Imprint: Birkhäuser, 2009.
Edición:1st ed. 2009.
Colección:Progress in Inflammation Research,
Temas:
Acceso en línea:Texto Completo

MARC

LEADER 00000nam a22000005i 4500
001 978-3-7643-8238-4
003 DE-He213
005 20220111135349.0
007 cr nn 008mamaa
008 100301s2009 sz | s |||| 0|eng d
020 |a 9783764382384  |9 978-3-7643-8238-4 
024 7 |a 10.1007/978-3-7643-8238-4  |2 doi 
050 4 |a RC927-927.5 
072 7 |a MJM  |2 bicssc 
072 7 |a MED083000  |2 bisacsh 
072 7 |a MJM  |2 thema 
082 0 4 |a 616.723  |2 23 
245 1 0 |a New Therapeutic Targets in Rheumatoid Arthritis  |h [electronic resource] /  |c edited by Paul-Peter Tak. 
250 |a 1st ed. 2009. 
264 1 |a Basel :  |b Birkhäuser Basel :  |b Imprint: Birkhäuser,  |c 2009. 
300 |a XII, 228 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Progress in Inflammation Research,  |x 2296-4525 
505 0 |a B cell targets in rheumatoid arthritis -- Co-stimulatory pathways in the therapy of rheumatoid arthritis -- Immunobiology of IL-6 - Tocilizumab (humanised anti-IL-6 receptor antibody) for the treatment of rheumatoid arthritis -- Role of IL-1 in erosive arthritis, lessons from animal models -- Interleukin-15 -- IL-17 and Th17 cells, key players in arthritis -- Role of IL-18 in inflammatory diseases -- Chemokines and chemokine receptors -- Signaling pathways in rheumatoid arthritis -- Targeting oncostatin M in the treatment of rheumatoid arthritis -- Targeting the epigenetic modifications of synovial cells -- Perspectives in targeted therapy. 
520 |a The volume focuses on therapeutic targets that were identified after TNF blockade and that have recently been registered or are currently under development for the treatment of rheumatoid arthritis. Each chapter discusses the biological rationale in great detail, including in vitro work and work in animal models, and where appropriate, results from clinical trials. The book is written by an international authorship of experts in this field. It is of interest to rheumatologists, immunologists, internists, investigators in immunology and rheumatology as well as the pharmaceutical industry. 
650 0 |a Rheumatology. 
650 0 |a Immunology. 
650 0 |a Pharmacology. 
650 0 |a Cytology. 
650 1 4 |a Rheumatology. 
650 2 4 |a Immunology. 
650 2 4 |a Pharmacology. 
650 2 4 |a Cell Biology. 
700 1 |a Tak, Paul-Peter.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer Nature eBook 
776 0 8 |i Printed edition:  |z 9783764394097 
776 0 8 |i Printed edition:  |z 9783764382377 
776 0 8 |i Printed edition:  |z 9783034600743 
830 0 |a Progress in Inflammation Research,  |x 2296-4525 
856 4 0 |u https://doi.uam.elogim.com/10.1007/978-3-7643-8238-4  |z Texto Completo 
912 |a ZDB-2-SME 
912 |a ZDB-2-SXM 
950 |a Medicine (SpringerNature-11650) 
950 |a Medicine (R0) (SpringerNature-43714)